Vanda Pharma Files Definitive Additional Proxy Materials

TL;DR

Vanda Pharma dropped more proxy docs, no fee. Shareholders get updated info.

AI Summary

Vanda Pharmaceuticals Inc. is mailing a definitive additional material proxy statement to its stockholders on May 13, 2024. This filing is related to the company's proxy materials and does not require a filing fee. The company is incorporated in Delaware and its principal business address is in Washington, D.C.

Why It Matters

This filing indicates Vanda Pharmaceuticals is providing updated or supplementary information to shareholders regarding proxy matters, which could influence voting decisions on corporate governance or strategic issues.

Risk Assessment

Risk Level: low — This is a routine filing of proxy materials, not indicating any immediate financial or operational risk.

Key Players & Entities

• Vanda Pharmaceuticals Inc. (company) — Registrant
• 20240513 (date) — Filing Date
• 20240513 (date) — Date as of Change
• 0001347178 (company) — Central Index Key
• 2834 (industry_code) — Standard Industrial Classification
• DE (state) — State of Incorporation
• 1231 (date) — Fiscal Year End
• 001-34186 (company) — SEC File Number
• 202-734-3400 (phone_number) — Business Phone
• 2200 PENNSYLVANIA AVE NW (address) — Business Street 1

FAQ

Filing Documents

• d833587ddefa14a.htm (DEFA14A) — 11KB
• g833587g0511073627822.jpg (GRAPHIC) — 9KB
• 0001193125-24-137238.txt ( ) — 24KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Vanda Pharmaceuticals Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. The following is a copy of a letter Vanda Pharmaceuticals Inc. began mailing to stockholders on May 13, 2024. May 13, 2024 Dear Stockholder: We have previously sent you proxy materials for the upcoming Annual Meeting of Stockholders of Vanda Pharmaceuticals Inc., which will be held virtually on May 17, 2024 at 9:00 a.m. Eastern Time. Vanda Pharmaceuticals Board of Directors unanimously recommends that stockholders vote FOR all proposals on the agenda. Your vote is important, no matter how many or how few shares you may own. Whether or not you plan to attend the virtual Annual Meeting, if you have not already done so, please vote TODAY by telephone or via the Internet. By Order of the Board of Directors, /s/ Timothy Williams Timothy Williams Senior Vice President, General Counsel and Secretary REMEMBER: You can vote by telephone or via the Internet. If you have any questions, or need assistance in voting your shares, please call our proxy solicitor, INNISFREE M&A INCORPORATED TOLL-FREE, at 877-750-0870

View Full Filing

View this DEFA14A filing on SEC EDGAR